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Abstract
Background: Fatty acid synthase (FASN) is an enzyme synthesized by the liver and plays an important role in
lipogenesis. The present study aimed to investigate whether serum FASN concentration may provide a direct link
between HIV and/or HCV viral infections and lipid metabolic disorders commonly observed in HIV/HCV-infected
patients.
Methods: We evaluated serum FASN concentration in 191 consecutive HIV-infected patients in the absence or
presence of HCV co-infection. For comparison, 102 uninfected controls were included. Metabolic and inflammatory
phenotype was also compared with respect to the presence of HCV co-infection.
Results: Serum FASN concentration was significantly higher in HIV-infected patients than in healthy participants
and HCV co-infected patients showed higher levels than those without co-infection. Levels were also affected by
treatment regimen, but marginally influenced by virological variables. Insulin concentration was the sole variable
among metabolic parameters that demonstrated a significant correlation with serum FASN concentrations. Serum
alanine aminotransferase (ALT) values correlated significantly with serum FASN concentration and provided the
best discrimination with respect to the presence or absence of HCV co-infection. In multivariate analysis, only ALT,
monocyte chemoattractant protein-1 (MCP-1) and the presence of antiretroviral treatment regimen significantly
contributed to explain serum FASN concentration in HIV/HCV co-infected patients.
Conclusion: Serum FASN concentration is significantly increased in HIV-infected individuals. The release of FASN
into the circulation is further enhanced in patients who are co-infected with HCV. Subsequent studies should
explore the usefulness of this indicator to monitor the effect of viral infections on disease progression and survival.
Background
The life expectancy of HIV-infected patients has drama-
tically improved with the use of antiretroviral therapies.
Unfortunately, the spectrum of metabolic alterations
and concurrent diseases, especially cardiovascular com-
plications, is being expanded gradually and more than
10% of HIV-infected patients experience life-threatening
clinical manifestations that could be treated and/or pre-
vented [1]. Although HIV-related metabolic alterations
have been attributed, at least in part, to the use of
antiretroviral treatments, both dyslipidemia and insulin
resistance can also be observed in treatment-naïve HIV-
infected patients suggesting a metabolically deleterious
role for the HIV infection itself [2,3].
The mechanism by which HIV alters lipid metabolism
in an infected cell is an issue largely unresolved; how-
ever, it was recently reported that HIV replication can
significantly alter the expression of key cellular proteins
closely involved in the maintenance of normal metabolic
pathways [4,5]. Proteomic studies by Chan et al [4] initi-
ally reported upregulation of Fatty Acid Synthase
(FASN) after HIV infection of cultured cells in vitro.
Their findings causally associated this lipogenic enzyme
- which remained undetectable in uninfected control
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infection. Rasheed et al [5] further confirmed and
expanded the notion that HIV replication alone (i.e.
without any influence of antiviral drugs, or other human
genetic factors) notably and specifically enhances pro-
duction of FASN and other important proteins that
mostly participate in lipid metabolism. FASN is also sig-
nificantly up-regulated during infection with HCV [6,7],
a frequent co-infection in HIV-patients [8]. We have
therefore hypothesized that measurement of circulating
FASN may provide a direct link between HIV and/or
HCV viral infections and lipid metabolic disorders com-
monly observed in HIV/HCV-infected patients.
FASN, a 250-kDa cytosolic multi-enzyme that is the
major responsible for the de novo lipogenesis, functions
normally in the liver whereas it is minimally expressed
in most other normal human tissues [9]. FASN overex-
pression and the subsequent change in cell lipogenic
phenotype may therefore be crucial in determining the
fate of such cell in response to different stimuli. This
notion has been already documented in human cancer
pathogenesis. FASN is highly expressed in most human
cancers and its inhibition leads to selective apoptotic
death of cancer cells both in vitro and in vivo [10]. Cul-
tured cancer cells can excrete immunoreactive FASN
into the extracellular space and the detection of signifi-
cant amounts of FASN in the blood of patients with
breast, prostate, and ovarian cancer may also represent a
potential biomarker for human cancer because serum
FASN concentration is further increased in the late
(metastatic) stages of human malignancies [11-14].
Although the ultimate mechanism regulating the extra-
cellular release of FASN remains largely undefined
[14,15], we might envisage that serum FASN concentra-
tions would become significantly altered in HIV-infected
patients with respect to healthy controls and this could
be related to the presence of HCV co-infection.
Methods
Participants
Patients included in this study attended the Hospital
Universitari de Sant Joan in Reus, Spain. We performed
a cross-sectional study in 191 consecutive HIV-infected
patients who accepted the invitation to participate in
the study and provided fully informed consent. Criteria
for inclusion consisted of age greater than 18 years, no
pre-existent AIDS-related opportunistic diseases and the
absence of acute disease or clinical signs of inflamma-
tion. Patients with clinical or analytical evidence of renal
insufficiency, cancer, neurological disorders or major
liver damage were excluded. To avoid any possible bias,
inclusion in the study was evaluated by personnel not
directly responsible for these patients. The study was
approved by the local Ethics Committee in accordance
with the Declaration of Helsinki. For comparisons of
selected variables we included a general population-
based control group of unrelated subjects (n = 102), free
of HIV and HCV infection or any other inflammatory
or metabolic alteration. Further details of the control
group have been described elsewhere [16].
Clinical and laboratory studies
Detailed clinical characteristics of each subject were
recorded and a thorough physical examination was per-
formed during the interview. We recorded data regard-
ing HIV/HCV infections including opportunistic
infections, mode of HIV transmission, CD4 cell count
and HIV/HCV viral loads, HCV genotypes, and details
of the current and past antiretroviral therapy. Lipody-
strophy was defined as the presence of body-fat changes
that included subcutaneous lipoatrophy (hollow cheeks,
prominent superficial veins in the limbs or flattening of
the buttocks) and/or lipohypertrophy (central obesity,
breast enlargement or dorsocervical fat pad). Data con-
cerning classical cardiovascular risk factors and labora-
tory variables were also included. Blood pressure was
determined according to standardized methods. Body-
mass index was defined as weight (kg)/height (m
2).
Fasting serum glucose, insulin, C-reactive protein, apoli-
poprotein A I, cholesterol, non-esterified fatty acids
(NEFAs) and triglycerides were measured with the auto-
matic analyzer LXi 725-Synchron (Beckman Coulter,
Fullerton, California, USA) using enzymatic assays or
chemiluminescent immunoassays. HDL-cholesterol and
LDL-cholesterol levels were measured as described
[17,18]. CD4+ and CD8+ T cells were counted using
FACscan flow cytometry (Becton Dickinson, Madrid,
Spain). Interleukin-6 (IL-6), interleukin-8 (IL-8) and
monocyte chemoattractant protein-1 (MCP-1) were
measured by a multiplex cytometric bead-based assay
(FlowCytomix Multiplex; BenderMedsystems, Vienna,
Austria) and were analyzed in an EPICS-XL-MCL flow
cytometer (Beckman-Coulter, Fullerton, CA) following
the manufacturer’s protocol. Circulating levels of the
extracellular form of FASN were measured by ELISA
(FASgen Inc., Baltimore, MA).
Statistical analysis
Results are expressed as the mean (S.E.M) unless other-
wise indicated. The Kolmogorov-Smirnov test was
applied to check the normality of the variables. ANOVA
was used to test the differences in continuous variables
and the chi-square test was used for categorical vari-
ables. Non-parametric tests were used when appropriate.
We performed multiple linear regression of FASN as a
dependent variable; included in the model were classical
variables and those variables for which the univariable
analysis showed a p-value of at least 0.1 and collineality
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values greater than 0.05 denote statistical significance.
The SPSS 17.0 package was used to perform the statisti-
cal analysis.
Results
Most HIV-infected patients in this study were smokers
(80.6%), 127 (66.5%) were male, and their ages ranged
from 29 years to 64 years. 114 (59.7%) had undetectable
HIV-1 viral load. The predominant cause of infection
was intravenous drug abuse (59.2%) and in the remain-
ing patients, sexual factors were positively identified.
Mean time since first serologic evidence of HIV infec-
tion was 4.29 (0.3) years. Obesity was not found in these
patients but 47 (24.1%) showed severe lipodystrophy.
115 (60.2) patients were co-infected with HCV. 64
patients were treated with protease inhibitor (PI)-con-
taining regimen, 76 with non-nucleoside analogues
reverse transcriptase inhibitors (NNRTI)-based therapy,
and 51 currently not receiving any type of antiretroviral
therapy for at least 6 months (Table 1).
Circulating levels of the extracellular form of FASN
were systematically and significantly higher in HIV-
infected patients than in healthy participants. Of note,
co-infection with HCV further significantly increased
serum FASN concentration (Figure 1A). Moreover,
circulating FASN levels were significantly affected by the
presence of antiretroviral treatment. As shown in Figure
1B, untreated HIV-infected patients had higher levels of
circulating FASN than those patients under antiretro-
viral therapy. However, serum FASN levels were mar-
ginally affected by the type of antiretroviral treatment.
Both in the healthy control group and in the HIV-
infected group we failed to observe significant associa-
tions between age or gender and serum FASN concen-
trations. However, a significant association was found in
women with undetectable HIV viral load when HIV-
infected patients were segregated according to the pre-
s e n c eo fH C Vc o - i n f e c t i o n( F i g u r e1 B ) .G e n d e r - b a s e d
differences in serum FASN concentration were also
observed in patients undergoing an NNRTI-based anti-
retroviral treatment regimen (Figure 1C).
We then examined the metabolic phenotype in partici-
pants according to immunological and virologic vari-
ables such as HIV/HCV viral loads as well as HCV
genotype (Tables 2 and 3). Serum FASN concentration
was not influenced by any virologic variable considered
here but there was a significant (p = 0.02) correlation
(r = 0.28) between serum FASN concentration and lym-
phocyte T CD4+ count but only in those patients with
detectable HIV viral load, suggesting that enhanced
levels of extracellular FASN might come, at least in part,
from lymphocyte T CD4+ T cells with active viral repli-
cation. Patients with lipodystrophy, in which distribution
of HCV co-infected patients was identical to that of the
whole group, also showed similar serum FASN concen-
trations [9.7 (3.2) μg/L] with respect to patients without
such condition [10.4 (4.1) μg/L]. There was also a trend
towards higher HOMA-IR values in HCV co-infected
patients which was significantly altered by NNRTI-
regimen treatment and that positively correlated with
serum FASN concentrations. HIV infection caused a
significant and deleterious effect on HDL-cholesterol,
apolipoprotein AI and triglycerides concentrations irre-
spective of HCV co-infection and treatment regimen in
comparison with the healthy group. However, we failed
to identify statistically significant changes in serum
NEFAs concentrations among patients with HCV
co-infection or among patients without co-infection.
Assessed inflammatory biomarkers were consistently
elevated in HCV co-infected patients with respect to
healthy participants, although the differences were not
statistically significant for serum IL-8. Serum MCP-1
and CRP concentrations were significantly increased in
HIV-infected patients irrespective to antiretroviral treat-
ment, while co-infection did not result in further differ-
ences (Figure 2A and 2B). We could not discriminate
serum IL-8 and IL-6 concentrations of the control
Table 1 Demographic and clinical characteristics of
HIV-infected patients (n = 191)
Characteristics Values
Age, years 38.8 (0.51)
Gender, male (%) 127 (66.5)
BMI, kg/m
2 22.93 (0.26)
Current smokers, n (%) 154 (80.6)
Lipodystrophy, n (%) 47 (24.1)
Time of sero-prevalence, years 4.29 (0.3)
Risk factors for HIV, n (%)
Intravenous drug users 113 (59.2)
Heterosexual contact 54 (28.3)
Male homosexual contact 24 (12.5)
Treatment scheme, n (%)
Untreated 51 (26.7)
Non-nucleoside analogues 76 (39.8)
Protease inhibitors 64 (33.5)
Undetectable HIV-1 viral load
a, n (%) 114 (59.7)
CD4+ T lymphocyte count, cells/mL 459 (22.8)
HCV co-infection, n (%) 115 (60.2)
HCV genotypes, %
I 78.3
II 3.8
III 14.9
IV 3.0
Log-HCV viral load, copies/mL 5.89 (1.14)
Values are the mean and the standard errors of the mean (S.E.M.), unless
otherwise indicated.
a Limit of detection: 40 copies/mL.
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and 2D). We also found significant correlations between
serum MCP-1 and serum FASN concentrations that
were not evident for the serum CRP concentration
(Figure 3A and 3B). However, serum MCP-1 concentra-
tion was not correlated with any virological parameter
above mentioned.
Among variables measured to ascertain the metabolic
phenotype, only the serum insulin concentration showed
a significant correlation with serum FASN, an associa-
tion that was significant in both co-infected and non-
co-infected patients (Figure 3C). As expected, serum
aminotransferases were significantly higher in HCV
co-infected patients, suggesting possible hepatic cellular
Figure 1 Circulating levels of the extracellular form of FASN. Distribution of serum FASN concentrations according to the presence of
antiretroviral treatment (A) or to the presence of HCV co-infection (B) in HIV-infected patients and in healthy participants; gender differences
were only appreciable in patients with undetectable HIV-1 viral load (C) or in those undergoing the NNRTI-based antiretroviral treatment
regimen (D).
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aminotransferase (ALT) values provided the best discri-
mination with respect to the presence or absence of
HCV co-infection and correlated significantly with
serum FASN concentration irrespective of the condition
of co-infection (Figure 4). In multivariate analysis only
ALT, MCP-1 and the presence of treatment regimen
significantly contributed to explain serum FASN
concentration in HIV-patients co-infected with HCV.
This relationship, however, was not maintained in
patients not infected by HCV (Table 4).
Discussion
It is currently considered that during metastasic pro-
gression of human malignancies the intracellular FASN
is up-regulated and over-expressed and the excess is
finally released from the cytosol to the circulation in a
stage-related manner [11-14]. Using a proteomics
Table 2 Metabolic profile of healthy participants and HIV-infected patients segregated according to HCV co-infection
and HIV-1 viral load
HIV-infected patients
Control group Non-HCV co-infected group HCV co-infected group
(n = 102) VL < 40 copies/mL VL > 40 copies/mL VL < 40 copies/mL VL > 40 copies/mL
(n = 47) (n = 29) (n = 67) (n = 48)
FASN, μg/L 3.36 (0.92) 5.83 (1.34)
a 5.08 (1.74) * 12.69 (2.01)
c 14.41 (2.91)
c
NEFA, mmol/L 0.65 (0.04) 0.62 (0.06) 0.64 (0.06) 0.63 (0.04) 0.61 (0.05)
Glucose, mmol/L 4.96 (0.16) 5.61 (0.20)
c 5.2 (0.14)
b 5.42 (0.12)
c 5.16 (0.10)
b
Insulin, pmol/L 64.6 (6.59) 69.22 (9.68) 47.95 (6.11)
a,* 84.40 (10.79)
a 76.31 (11.82)
HOMA-IR 1.15 (0.20) 1.33 (0.18) 0.92 (0.14)
a,* 1.64 (0.22)
a 1.48 (0.25)
Cholesterol, mmol/L 5.27 (0.12) 5.52 (0.19) 5.14 (0.23) 4.74 (0.15)
c 4.41 (0.16)
c
HDL-cholesterol, mmol/L 1.36 (0.03) 1.24 (0.09)
a 1.15 (0.08)
b 1.21 (0.05)
b 1.07 (0.05)
c, *
LDL-cholesterol, mmol/L 3.19 (0.79) 3.28 (0.17) 2.96 (0.17) 2.71 (0.13)
c 2.38 (0.13)
c
Triglyceride, mmol/L 1.27 (0.9) 3.00 (0.47)
c 3.11 (1.01) 2.04 (0.18)
c 3.24 (1.09)
c
Apolipoprotein AI, g/L 1.69 (0.05) 1.44 (0.05)
c 1.26 (0.04)
c, ** 1.40 (0.03)
c 1.33 (0.04)
c
Alanine aminotransferase, μKat/L 0.46 (0.02) 0.45 (0.03) 0.51 (0.04) 0.98 (0.11)
c 0.97 (0.11)
c
Aspartate aminotransferase, μKat/L 0.41 (0.02) 0.41 (0.03) 0.47 (0.08) 0.88 (0.09)
c 0.88 (0.99)
c
Values are the mean and the standard error of the mean (S.E.M.).
VL indicates HIV-1 viral load; HOMA-IR is homeostasis model assessment-estimated insulin resistance; NEFA is non-esterificated fatty acids.
a P<0 . 0 5 ,
b P < 0.01 and
c P < 0.001 with respect to control group; * P < 0.05 and ** P = 0.006 with respect to patients with VL < 40 copies/mL in the
corresponding group
Table 3 Metabolic profile of HIV-infected patients segregated according to HCV co-infection and antiretroviral therapy
Non-HCV co-infected group HCV co-infected group
Untreated NNRTI PI Untreated NNRTI PI
(n = 19) (n = 32) (n = 25) (n = 32) (n = 44) (n = 39)
FASN, μg/L 5.14 (2.10) 7.40 (1.81) 4.15 (1.00) 20.01 (4.0) 8.64 (1.51)
b 11.75 (2.41)
a
NEFA, mmol/L 0.53 (0.07) 0.63 (0.07) 0.77 (0.1) 0.65 (0.06) 0.67 (0.05) * 0.52 (0.04)
Glucose, mmol/L 5.21 (0.20) 5.77 (0.29) * 5.09 (0.09) 5.13 (0.13) 5.62 (0.19)
a 5.21 (011)
Insulin, pmol/L 41.91 (7.1) 70.74 (13.4)
a 62.23 (8.6)
a 71.35 (11.2) 103.2 (19.8) 72.24 (10.7)
HOMA-IR 0.80 (0.16) 1.38 (0.27)
a 1.14 (0.16) 1.41 (0.25) 2.06 (0.42) 1.36 (0.21)
Cholesterol, mmol/L 4.59 (0.24) 5.34 (0.23)
a,* 6.10 (0.28)
c 4.41 (0.19) 4.67 (0.23) 4.7 (0.16)
HDL-cholesterol, mmol/L 1.18 (0.09) 1.30 (0.12) 1.18 (0.10) 1.17 (0.07) 1.20 (0.05) * 1.09 (0.6)
LDL-cholesterol, mmol/L 2.69 (0.22) 3.10 (0.20) * 3.59 (0.23)
a 2.57 (0.15) 2.54 (0.18) 2.70 (1.15)
Triglyceride, mmol/L 1.57 (0.29) 2.60 (0.44)
a 4.87 (1.50)
b 2.99 (1.71) 2.35 (0.36)
a 2.17 (0.22)
b
Apolipoprotein AI, g/L 1.39 (0.06) 1.43 (0.07) 1.34 (0.06) 1.33 (0.06) 1.45 (0.04) * 1.32 (0.04)
Alanine aminotransferase, μKat/L 0.52 (0.10) 0.57 (0.11) 0.45 (0.06) 1.16 (0.16) 0.91 (0.11) 0.69 (0.07)
a
Aspartate aminotransferase, μKat/L 0.45 (0.07) 0.45 (0.04) 0.41 (0.08) 1.02 (0.13) 0.94 (0.14) 0.69 (0.07)
a
Values are the mean and the standard error of the mean (S.E.M.).
HOMA-IR is homeostasis model assessment-estimated insulin resistance; NEFA indicates non-esterificated fatty acids; NNRTI: non-nucleoside analogues reverse
transcriptase inhibitors; PI: protease inhibitors;
a P<0 . 0 5 ,
b P < 0.01 and
c P < 0.001 vs untreated patients of the corresponding group; * P < 0.05 with respect to PI-treated patients in the corresponding
group
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cantly up-regulated during both HIV infection and HCV
infection [4,5,7]. Our data confirm and extend further
these in vitro findings in a clinical setting revealing for
the first time that HIV-infected patients show significant
elevations in circulating serum FASN concentration
with respect to healthy uninfected donors. Moreover,
the increase in serum FASN concentration is even
greater in HIV-patients co-infected with HCV. FASN,
an intracellular protein, appears to exit cells during HIV
infection and this release into the circulation is exacer-
bated in the presence of HCV co-infection, a condition
that is frequently observed in HIV-infected patients.
Based on the gender dependencies that we observed (i.e.
women with undetectable HIV viral load or in those
undergoing NNRTI-based antiretroviral regimen), and
considering that women infected with HIV have a
higher rate of gonadal dysfunction [19], it could be
Figure 2 Circulating levels of pro-inflammatory biomarkers. Distribution of serum MCP-1 (A), C-reactive protein (B), interleukin-8 (C) and
interleukin-6 (D) concentrations in healthy subjects and HIV-infected patients segregated according to the presence of HCV co-infection and
antiretroviral therapy. TTM-indicates untreated patients; TTM+ indicates treated patients; * indicates p < 0.05.
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at least in part, from stimulatory effects of estrogen on
FASN gene expression which, in turn, will result in
enhanced release of FASN protein [20-22]. Conversely,
and perhaps surprisingly, we did not observe any signifi-
cant relationship between circulating levels of the extra-
cellular form of FASN and HIV-related dyslipidemia
and lipodystrophy, two conditions in which enhanced
endogenous fatty acid synthesis is closely linked to the
accumulation of lipids and disproportionate distribution
of tissue-associated fats. Although cytosolic FASN, by
the coordinated action of its seven active sites, catalyzes
all of the necessary reactions in the synthesis of palmi-
tate [23-25], we failed also to identify statistically signifi-
cant changes in serum NEFAs concentrations in both
groups of HIV-infected patients, with and without HCV
co-infection. Therefore, our findings support a model in
which, upon infection with HIV and/or HCV, changes
in circulating levels of extracellular FASN take place
through molecular mechanisms likely unrelated to
established pathways that regulate the intracellular
FASN expression [9,10,23-25]. Notably, integration of
HIV into the host cell chromosome occurs preferentially
within genes. Particularly, insulin receptor (IRS),
19p13.3-13.2, is one of the identified integration sites
[26] and the knockdown of this gene results in a signifi-
cant up-regulation of FASN [27]. It is plausible, there-
fore, that increased levels of serum FASN are not a
mere epiphenomenon related to cell destruction and
leakage but rather to a pathophysiologic response occur-
ring during the viral infection.
In multivariate analysis, serum MCP-1, but not other
inflammatory biomarkers, significantly contributed to
explain serum FASN concentration in HCV co-infected
patients despite the strong association with serum ALT
activity and treatment regimen. This is not unexpected
as we have already shown that serum MCP-1 concentra-
tion may be a reliable marker of inflammation in hepatic
derangements in patients with chronic liver disease, a
characteristic that is not shared by serum CRP concen-
tration [28]. As previously described [29], HCV co-infec-
tion increased serum IL-8 levels with respect to healthy
individuals. Surprisingly, our comparison did not reach
statistically significance, suggesting that IL-8 liver
Figure 3 Relationship between FASN concentration, inflammation and metabolism. Correlation between serum FASN concentration and
MCP-1 (A), C-reactive protein (B) and insulin (C) concentrations in HIV-infected patients. (Opened circles indicate non-HCV co-infected patients;
and closed circles indicate HCV co-infected patients).
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HIV therapy as shown in Figure 2D. Moreover, the cor-
relation between serum insulin and serum FASN was
maintained irrespective of HCV co-infection or altered
ALT values in HIV-infected patients.
Abnormalities of glucose regulation, including
impaired glucose tolerance and insulin resistance, are
often developed among HIV-infected patients, and co-
infection with HCV appears to exacerbate insulin resis-
tance in these patients [30-33]. Insulin resistance in this
population may result from antiviral medication, effects
of HIV and/or HCV per se, or from other indirect
effects, such as fat redistribution. Considering that
increased MCP-1 forms also a vicious adipokine net-
work causing insulin resistance and metabolic syndrome
[34], both the chronic viral state itself and the host
immune response can give rise to glucose and lipid
metabolic disorders which, in turn, are risk factors for
hepatic damage. Therefore, it is tempting to suggest that
molecular determinants of HIV/HCV action on FASN
release are closely linked to the overall metabolic regula-
tion. In this scenario, increased concentrations of serum
FASN might universally occur in metabolic disorders in
which insulin resistance could be prominent. Supporting
this notion, we and others have found that serum FASN
concentration is increased in patients with non-alcoholic
steatohepatitis or chronic liver impairment [35,36]. We
have also found higher concentrations of circulating
FASN in patients with type 2 diabetes [9]. Administra-
tion of insulin sensitizers significantly prevented FASN
release from cultured human adipose tissue explants
whereas treatment with inflammatory stimuli increased
the amount of extracellular FASN [9]. We now add
chronic infection with HIV/HCV as a novel pro-insulin
resistance setting in which serum FASN concentration
is significantly increased.
We have also provided experimental evidence to sug-
gest that FASN release is an active and controlled pro-
cess through the activation of AMP-activated protein
kinase (AMPK) [15], a key enzyme that regulates the
body energy balance [37-39]. We acknowledge that the
ultimate mechanisms through which HIV/HCV infec-
tions influence the FASN release cannot by addressed
by our study but HIV/HCV-induced changes on AMPK
Figure 4 Relationship between FASN concentration and liver disease. Correlation between serum FASN concentration and alanine
aminotransferase activity both in non-HCV co-infected (A) and HCV co-infected (B) HIV-infected patients. Analyses for the discrimination of HCV
co-infected patients using the receiver-operating curves (C) for serum (1) alanine aminotransferase activity, (2) aspartate aminotransferase activity,
(3) FASN concentration, and (4) MCP-1 concentrations showed that the relative contributions of FASN and MCP-1 were significant but negligible.
The area under the curve values (95% CI), were respectively: 0.834 (0.764-0.904), 0.754 (0673-0.835), 0.713 (0.626-0.801) and 0.652 (0.560-0.744).
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slow-growing viruses that should maintain beneficial
host cell functions for an extended period as signs of
disease do not usually show up until months or years
after initial exposure. This requires a strict control of
cellular AMPK because intense response and energy uti-
lization could be deleterious to the viral infection [40].
We hypothesize that upon AMPK activation, the extra-
cellular release of excess FASN may provide a rapid
mechanism to prevent further energy consumption.
Conversely, if we assume that FASN up-regulation is
important in the pathogenesis of HIV and HCV infec-
tion, as it has been already demonstrated in infections
by the hepatitis B virus and the coxsackievirus B3 [41],
it is conceivable that FASN might be a potential thera-
peutic target for an antiviral therapy.
Conclusions
Serum FASN concentration is significantly increased in
HIV-infected patients. The release of the extracellular
form of FASN into the circulation is further enhanced
in patients who are co-infected with HCV or are not
undergoing antiretroviral therapy. Subsequent studies
should explore the usefulness of serum FASN concen-
tration measurement to monitor the effects viral
infections on disease progression and survival as well as
the putative prognostic or diagnostic role for patients in
whom repetitive viral infections and associated diseases
are expected.
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